Showing posts with label microchip. Show all posts
Showing posts with label microchip. Show all posts

Thursday, 26 January 2012

Scientists Produce World's First Magnetic Soap


The liquid crystal progression of each surfactant was investigated by the solvent penetration method (i.e. phase cut). A small amount of surfactant was placed on a microscope slide under a coverslip. The slide was mounted on the cover slide and heated until the sample was fluid and completely isotropic. After slow cooling (1.0 °C min-1) to 25 °C, a drop of water was added to the edge of the coverslip. As the water penetrated the surfactant, a concentration gradient was established, from water at one side to pure surfactant at the other, enabling the entire range of mesophases to be observed in the field of view. (Credit: Image courtesy of Institut Laue-Langevin (ILL))


ScienceDaily (Jan. 23, 2012) — Scientists from Bristol University have developed a soap, composed of iron rich salts dissolved in water, that responds to a magnetic field when placed in solution. The soap’s magnetic properties were shown with neutrons at the Institut Laue-Langevin to result from tiny iron-rich clumps that sit within the watery solution. The generation of this property in a fully functional soap could calm concerns over the use of soaps in oil-spill clean ups and revolutionise industrial cleaning products.


Scientists have long been searching for a way to control soaps (or surfactants as they are known in industry) once they are in solution to increase their ability to dissolve oils in water and then remove them from a system. The team at Bristol University have previously worked on soaps sensitive to light, carbon dioxide or changes in pH, temperature or pressure. Their latest breakthrough, reported inAngewandte Chemie, is the world’s first soap sensitive to a magnetic field.


Ionic liquid surfactants, composed mostly of water with some transition metal complexes (heavy metals like iron bound to halides such as bromine or chlorine) have been suggested as potentially controllable by magnets for some time, but it had always been assumed that their metallic centres were too isolated within the solution, preventing the long-range interactions required to be magnetically active.
The team at Bristol, lead by Professor Julian Eastoe produced their magnetic soap by dissolving iron in a range of inert surfactant materials composed of chloride and bromide ions, very similar to those found in everyday mouthwash or fabric conditioner. The addition of the iron creates metallic centres within the soap particles.
To test its properties, the team introduced a magnet to a test tube containing their new soap lying beneath a less dense organic solution. When the magnet was introduced the iron-rich soap overcame both gravity and surface tension between the water and oil, to levitate through the organic solvent and reach the source of the magnetic energy, proving its magnetic properties.
Once the surfactant was developed and shown to be magnetic, Prof Eastoe’s team took it to the Institut Laue-Langevin, the world’s flagship centre for neutron science, and home to the world’s most intense neutron source, to investigate the science behind its remarkable property.
When surfactants are added to water they are known to form tiny clumps (particles called micelles). Scientists at ILL used a technique called “small angle neutron scattering (SANS)” to confirm that it was this clumping of the iron-rich surfactant that brought about its magnetic properties.
Dr Isabelle Grillo, responsible of the Chemistry Laboratories at ILL: “The particles of surfactant in solution are small and thus difficult to see using light but are easily revealed by SANS which we use to investigate the structure and behaviour of all types of materials with typical sizes ranging from the nanometer to the tenth of micrometer.”
The potential applications of magnetic surfactants are huge. Their responsiveness to external stimuli allows a range of properties, such as their electrical conductivity, melting point, the size and shape of aggregates and how readily its dissolves in water to be altered by a simple magnetic on and off switch. Traditionally these factors, which are key to the effective application of soaps in a variety of industrial settings, could only be controlled by adding an electric charge or changing the pH, temperature or pressure of the system, all changes that irreversibly alter the system composition and cost money to remediate.
Its magnetic properties also makes it easier to round up and remove from a system once it has been added, suggesting further applications in environmental clean ups and water treatment. Scientific experiments which require precise control of liquid droplets could also be made easier with the addition of this surfactant and a magnetic field.
Professor Julian Eastoe, University of Bristol: “As most magnets are metals, from a purely scientific point of view these ionic liquid surfactants are highly unusual, making them a particularly interesting discovery. From a commercial point of view, though these exact liquids aren’t yet ready to appear in any household product, by proving that magnetic soaps can be developed, future work can reproduce the same phenomenon in more commercially viable liquids for a range of applications from water treatment to industrial cleaning products.”
Peter Dowding an industrial chemist, not involved in the research: “Any systems which act only when responding to an outside stimulus that has no effect on its composition is a major breakthrough as you can create products which only work when they are needed to. Also the ability to remove the surfactant after it has been added widens the potential applications to environmentally sensitive areas like oil spill clean ups where in the past concerns have been raised.”

Sunday, 13 November 2011

Magnetic attraction: Microchip demonstrates concept of 'MRAM for biomolecules'

ScienceDaily (Oct. 19, 2011) — Researchers from the National Institute of Standards and Technology (NIST) and University of Colorado Boulder (CU) have developed a low-power microchip that uses a combination of microfluidics and magnetic switches to trap and transport magnetic beads. The novel transport chip may have applications in biotechnology and medical diagnostics.

A key innovation in the new chip is the use of magnetic switches like those in a computer random access memory. As described in a new paper, the NIST/CU team used the chip to trap, release and transport magnetic beads that potentially could be used as transport vehicles for biomolecules such as DNA.

Conventional microfluidics systems use pumps and valves to move particles and liquids through channels. Magnetic particle transport microchips offer a new approach to microfluidics but generally require continuous power and in some cases cooling to avoid sample damage from excessive heating. The NIST/CU technology eliminates these drawbacks while offering the possibility for random access two-dimensional control and a memory that lasts even with the power off.

The demo chip features two adjacent lines of 12 thin-film magnet switches called spin valves, commonly used as magnetic sensors in read heads of high-density computer disk drives. In this case, however, the spin valves have been optimized for magnetic trapping. Pulses of electric current are used to switch individual spin valve magnets "on" to trap a bead, or "off" to release it, and thereby move the bead down a ladder formed by the two lines (see video clip at: http://www.nist.gov/pml/electromagnetics/magnetics/magnetic-101311.cfm). The beads start out suspended in salt water above the valves before being trapped in the array.

"It's a whole new way of thinking about microfluidics," says NIST physicist John Moreland. "The cool thing is it's a switchable permanent magnet -- after it's turned on it requires no power. You beat heat by switching things quickly, so you only need power for less than a microsecond."

NIST researchers previously demonstrated that spin valves could be used to trap and rotate particles and recently were awarded two patents related to the idea of a magnetic chip.

Magnetic tags are used in bioassays such as protein and DNA purification and cell breakdown and separation. The chip demonstration provides a conceptual foundation for a more complex magnetic random access memory (MRAM) for molecular and cellular manipulation. For example, programmable microfluidic MRAM chips might simultaneously control a large number of beads, and the attached molecules or cells, to assemble "smart" tags with specified properties, such as an affinity for a given protein at a specific position in the array. NIST is also interested in developing cellular and molecular tags for magnetic resonance imaging (MRI) studies in which individual cells, such as cancer cells or stem cells, would be tagged with a smart magnetic biomarker that can be tracked remotely in an MRI scanner, Moreland says. Automated spin valve chips might also be used in portable instruments for rapid medical diagnosis or DNA sequencing.

The lead author of the new paper, Wendy Altman, did the research at NIST as a CU graduate student working on her doctoral thesis. Another author, Bruce Han, was a CU student in NIST's Summer Undergraduate Research Fellowship (SURF) program.

Recommend this story on Facebook, Twitter,
and Google +1:

Other bookmarking and sharing tools:

Story Source:

The above story is reprinted from materials provided by National Institute of Standards and Technology (NIST).

Note: ScienceDaily reserves the right to edit materials for content and length. For further information, please contact the source cited above.

Journal Reference:

Wendy R. Altman, John Moreland, Stephen E. Russek, Bruce W. Han, Victor M. Bright. Controlled transport of superparamagnetic beads with spin-valves. Applied Physics Letters, 2011; 99 (14): 143703 DOI: 10.1063/1.3645615

Note: If no author is given, the source is cited instead.

Disclaimer: Views expressed in this article do not necessarily reflect those of ScienceDaily or its staff.


View the original article here

Thursday, 23 June 2011

Improving health assessments with a single cell: Portable microchip for immune monitoring and clinical applications

ScienceDaily (May 23, 2011) — There's a wealth of health information hiding in the human immune system. Accessing it, however, can be very challenging, as the many and complex roles that the immune system plays can mask the critical information that is relevant to addressing specific health issues. Now, research led by scientists from the California Institute of Technology (Caltech) has shown that a new generation of microchips developed by the team can quickly and inexpensively assess immune function by examining biomarkers -- proteins that can reflect the response of the immune system to disease -- from single cells.

The scientists reported on their advanced technology in the May 22 online issue of Nature Medicine.

"The technology permits us for the first time to quantitatively measure the levels of many functional proteins from single, rare immune cells," says James Heath, the Elizabeth W. Gilloon Professor and professor of chemistry at Caltech and corresponding author of the study. "The functional proteins are the ones that are secreted by the cells, and they control biological processes such as cell replication and inflammation and, specific to our study, tumor killing."

In 2008, Heath -- an expert in molecular electronics and personalized medicine -- led the development of a "barcode chip" that, using just a pinprick's worth of blood, could measure the concentrations of dozens of proteins, including those that herald the presence of diseases like cancer and heart disease. This latest single-cell barcode chip (SCBC) device builds upon the success of that initial design, which is currently being utilized in diagnostic medical testing of certain cancer patients.

The researchers tested the chip by measuring a cancer patient's response to a type of cell-based immunotherapy designed to target and kill tumor cells. The only way to know if the therapy is doing its job is to measure many proteins at the same time from the individual cells that were targeting the tumor. The SCBC aced this test, generating readouts of a dozen secreted biomarkers -- each of which represented a distinct cell function -- and taking those readings from about a thousand single cells simultaneously.

The team was able to conduct a proof-of-concept study by looking at samples from a melanoma patient participating in the immunotherapy trials, and comparing those results to similar samples from three healthy subjects.

"This technology has the potential to be used routinely to monitor immune system performance," says Chao Ma, a graduate student in Heath's lab at Caltech's NanoSystems Biology Cancer Center and lead author of the Nature Medicine paper. "For example, it can be directly used to evaluate the effectiveness of certain classes of therapeutics, such as vaccines and other immunotherapies."

According to Ma, the technology is minimally invasive, cost-effective, and highly informative. The goal, he says, is to help physicians closely track the effectiveness of a therapy, and to rapidly alter or switch that therapy for the maximum benefit of the patient.

"The research fully demonstrates real-life clinical use of our revolutionary technology," Ma says.

The next step for the team will be to systematically apply the technology to clinical studies. The researchers have already begun to test the technology in additional patient populations, and to combine the SCBC with existing assays in order to get a more comprehensive picture of a therapy's efficacy.

In fact, the same study that showed the microchip's efficacy is already helping the researchers better evaluate the specific cancer immunotherapy trial, from which the patient in the study was drawn. "We are doing these same types of measurements on similar patients but at a significantly higher level of detail, and at many time points over the course of the cancer immunotherapy procedure," explains Heath. "It is helping us put together a 'movie' of the patient's immune system during the therapy, and it is providing us with some very surprising but also valuable insights into how the therapy works and how we might work with our UCLA colleagues to improve it."

"Application of this technology provides an unprecedented understanding of the human immune system by allowing an efficient and multiplexed functional readout of immune responses using limiting numbers of lymphocytes," says Antoni Ribas, associate professor of medicine and physician who led the clinical trial portion of the study at UCLA's Jonsson Comprehensive Cancer Center.

The other Caltech authors of the Nature Medicine paper, "A clinical microchip for evaluation of single immune cells reveals high functional heterogeneity in phenotypically similar T cells," are postdoctoral scholar Qihui Shi; Rong Fan, former postdoctoral scholar; former graduate students Habib Ahmad and Gabriel Kwong; and Chao-Chao Liu, former undergraduate student. Begonya Comin-Andiux, assistant professor of surgery; Thinle Chodon, assistant researcher of medicine; Richard C. Koya, assistant professor of surgery; and Caius G. Radu, associate professor of medical and molecular pharmacology from UCLA's Jonsson Comprehensive Cancer Center also contributed to the study.

The work was funded by the National Cancer Institute, the Ivy Foundation, the Jean Perkins Foundation, the California Institute for Regenerative Medicine, the Caltech/UCLA Joint Center for Translational Medicine, the Melanoma Research Alliance, and the National Institutes of Health.

Story Source:

The above story is reprinted (with editorial adaptations by ScienceDaily staff) from materials provided by California Institute of Technology. The original article was written by Katie Neith.

Journal Reference:

Chao Ma, Rong Fan, Habib Ahmad, Qihui Shi, Begonya Comin-Anduix, Thinle Chodon, Richard C Koya, Chao-Chao Liu, Gabriel A Kwong, Caius G Radu, Antoni Ribas, James R Heath. A clinical microchip for evaluation of single immune cells reveals high functional heterogeneity in phenotypically similar T cells. Nature Medicine, 2011; DOI: 10.1038/nm.2375

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.


View the original article here

Sunday, 5 June 2011

Improving health assessments with a single cell: Portable microchip for immune monitoring and clinical applications

ScienceDaily (May 23, 2011) — There's a wealth of health information hiding in the human immune system. Accessing it, however, can be very challenging, as the many and complex roles that the immune system plays can mask the critical information that is relevant to addressing specific health issues. Now, research led by scientists from the California Institute of Technology (Caltech) has shown that a new generation of microchips developed by the team can quickly and inexpensively assess immune function by examining biomarkers -- proteins that can reflect the response of the immune system to disease -- from single cells.

The scientists reported on their advanced technology in the May 22 online issue of Nature Medicine.

"The technology permits us for the first time to quantitatively measure the levels of many functional proteins from single, rare immune cells," says James Heath, the Elizabeth W. Gilloon Professor and professor of chemistry at Caltech and corresponding author of the study. "The functional proteins are the ones that are secreted by the cells, and they control biological processes such as cell replication and inflammation and, specific to our study, tumor killing."

In 2008, Heath -- an expert in molecular electronics and personalized medicine -- led the development of a "barcode chip" that, using just a pinprick's worth of blood, could measure the concentrations of dozens of proteins, including those that herald the presence of diseases like cancer and heart disease. This latest single-cell barcode chip (SCBC) device builds upon the success of that initial design, which is currently being utilized in diagnostic medical testing of certain cancer patients.

The researchers tested the chip by measuring a cancer patient's response to a type of cell-based immunotherapy designed to target and kill tumor cells. The only way to know if the therapy is doing its job is to measure many proteins at the same time from the individual cells that were targeting the tumor. The SCBC aced this test, generating readouts of a dozen secreted biomarkers -- each of which represented a distinct cell function -- and taking those readings from about a thousand single cells simultaneously.

The team was able to conduct a proof-of-concept study by looking at samples from a melanoma patient participating in the immunotherapy trials, and comparing those results to similar samples from three healthy subjects.

"This technology has the potential to be used routinely to monitor immune system performance," says Chao Ma, a graduate student in Heath's lab at Caltech's NanoSystems Biology Cancer Center and lead author of the Nature Medicine paper. "For example, it can be directly used to evaluate the effectiveness of certain classes of therapeutics, such as vaccines and other immunotherapies."

According to Ma, the technology is minimally invasive, cost-effective, and highly informative. The goal, he says, is to help physicians closely track the effectiveness of a therapy, and to rapidly alter or switch that therapy for the maximum benefit of the patient.

"The research fully demonstrates real-life clinical use of our revolutionary technology," Ma says.

The next step for the team will be to systematically apply the technology to clinical studies. The researchers have already begun to test the technology in additional patient populations, and to combine the SCBC with existing assays in order to get a more comprehensive picture of a therapy's efficacy.

In fact, the same study that showed the microchip's efficacy is already helping the researchers better evaluate the specific cancer immunotherapy trial, from which the patient in the study was drawn. "We are doing these same types of measurements on similar patients but at a significantly higher level of detail, and at many time points over the course of the cancer immunotherapy procedure," explains Heath. "It is helping us put together a 'movie' of the patient's immune system during the therapy, and it is providing us with some very surprising but also valuable insights into how the therapy works and how we might work with our UCLA colleagues to improve it."

"Application of this technology provides an unprecedented understanding of the human immune system by allowing an efficient and multiplexed functional readout of immune responses using limiting numbers of lymphocytes," says Antoni Ribas, associate professor of medicine and physician who led the clinical trial portion of the study at UCLA's Jonsson Comprehensive Cancer Center.

The other Caltech authors of the Nature Medicine paper, "A clinical microchip for evaluation of single immune cells reveals high functional heterogeneity in phenotypically similar T cells," are postdoctoral scholar Qihui Shi; Rong Fan, former postdoctoral scholar; former graduate students Habib Ahmad and Gabriel Kwong; and Chao-Chao Liu, former undergraduate student. Begonya Comin-Andiux, assistant professor of surgery; Thinle Chodon, assistant researcher of medicine; Richard C. Koya, assistant professor of surgery; and Caius G. Radu, associate professor of medical and molecular pharmacology from UCLA's Jonsson Comprehensive Cancer Center also contributed to the study.

The work was funded by the National Cancer Institute, the Ivy Foundation, the Jean Perkins Foundation, the California Institute for Regenerative Medicine, the Caltech/UCLA Joint Center for Translational Medicine, the Melanoma Research Alliance, and the National Institutes of Health.

Story Source:

The above story is reprinted (with editorial adaptations by ScienceDaily staff) from materials provided by California Institute of Technology. The original article was written by Katie Neith.

Journal Reference:

Chao Ma, Rong Fan, Habib Ahmad, Qihui Shi, Begonya Comin-Anduix, Thinle Chodon, Richard C Koya, Chao-Chao Liu, Gabriel A Kwong, Caius G Radu, Antoni Ribas, James R Heath. A clinical microchip for evaluation of single immune cells reveals high functional heterogeneity in phenotypically similar T cells. Nature Medicine, 2011; DOI: 10.1038/nm.2375

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.


View the original article here